Company's Presence at Meeting Highlights Recent Successes in Europe

ST. LOUIS, May 3 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that its computer-controlled magnetic navigation technology will be the subject of 12 presentations at four symposiums, three poster sessions, three oral abstract sessions, a case-based tutorial, and a presentation during the core curriculum portion of the Heart Rhythm 2005 Scientific Sessions, which will take place May 4-7 at the Ernest N. Morial Convention Center in New Orleans, LA.

Electrophysiologists from hospitals in Europe and the United States will present their views on experiences relating to mapping and ablation, cardiac resynchronization therapy and other applications of the Stereotaxis Niobe(R) Magnetic Navigation System.

Since Biosense Webster received CE Mark approval for the Celsius RMT(TM) and NaviStar RMT(TM) ablation catheters, and the CARTO RMT(TM) navigation and ablation system at the end of the first quarter, Stereotaxis' technology has been in frequent clinical usage in Europe. Specifically, more than 100 European procedures have been completed since the CE Marking authorizations were obtained, an average of one per day among those sites that have installed both the Stereotaxis system and the Biosense CARTO(TM) RMT navigation and ablation system. These ablation catheters are not currently available in the United States.

"We are very pleased with the significant utilization of our system and the adoption of the Biosense catheters and CARTO system in Europe," said Bevil Hogg, Stereotaxis' President and CEO. "We believe that the results we are achieving in Europe, which have exceeded our expectations, provide insight into the benefits that physicians and patients are realizing from the system and will provide a solid foundation of experiences from which we can build on in the future when ablation catheters are approved for marketing in the U.S."

Recent procedures being performed in Europe include successful treatment of Cardiac Resynchronization Therapy through placement of Bi-Ventricular pacing leads (Bi-V), several forms of Supraventricular Tachycardia; including AV Node Reentry Tachycardia (AVNRT), Atrial Flutter, Wolff-Parkinson-White syndrome (WPW); as well as the complex treatment of Atrial Fibrillation (AFIB).

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S. and Europe.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

     Contacts:
     Stereotaxis, Inc.
     314-615-6957
     Jim Stolze, Chief Financial Officer
     jstolze@stereotaxis.com

     Noonan Russo
     212-845-4269
     Brian Ritchie (investors)
     brian.ritchie@eurorscg.com

SOURCE  Stereotaxis, Inc.
    -0-                             05/03/2005
    /CONTACT:  Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,
+1-314-615-6957, jstolze@stereotaxis.com; or Brian Ritchie (investors) of
Noonan Russo, +1-212-845-4269, brian.ritchie@eurorscg.com/
    (STXS)

CO:  Stereotaxis, Inc.
ST:  Missouri, Louisiana
IN:  HEA MTC BIO CPR
SU:  TDS

EA
-- NYTU049 --
1823 05/03/2005 08:15 EDT http://www.prnewswire.com